- Home
- CHRS vs OXSQ Comparison
CHRS vs OXSQ Comparison
Compare CHRS & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- OXSQ
- Stock Information
- Founded
- CHRS 2010
- OXSQ 2003
- Country
- CHRS United States
- OXSQ United States
- Employees
- CHRS 235
- OXSQ N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- OXSQ Blank Checks
- Sector
- CHRS Health Care
- OXSQ Finance
- Exchange
- CHRS Nasdaq
- OXSQ Nasdaq
- Market Cap
- CHRS 134.4M
- OXSQ 175.2M
- IPO Year
- CHRS 2014
- OXSQ N/A
- Fundamental
- Price
- CHRS $1.21
- OXSQ $2.72
- Analyst Decision
- CHRS Strong Buy
- OXSQ
- Analyst Count
- CHRS 4
- OXSQ 0
- Target Price
- CHRS $5.38
- OXSQ N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- OXSQ 417.6K
- Earning Date
- CHRS 03-12-2025
- OXSQ 03-14-2025
- Dividend Yield
- CHRS N/A
- OXSQ 15.50%
- EPS Growth
- CHRS N/A
- OXSQ N/A
- EPS
- CHRS N/A
- OXSQ N/A
- Revenue
- CHRS $304,340,000.00
- OXSQ $44,787,853.00
- Revenue This Year
- CHRS $2.47
- OXSQ N/A
- Revenue Next Year
- CHRS N/A
- OXSQ N/A
- P/E Ratio
- CHRS N/A
- OXSQ N/A
- Revenue Growth
- CHRS 44.19
- OXSQ N/A
- 52 Week Low
- CHRS $0.66
- OXSQ $2.40
- 52 Week High
- CHRS $2.87
- OXSQ $3.29
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- OXSQ 59.94
- Support Level
- CHRS $1.03
- OXSQ $2.62
- Resistance Level
- CHRS $1.23
- OXSQ $2.74
- Average True Range (ATR)
- CHRS 0.13
- OXSQ 0.04
- MACD
- CHRS -0.02
- OXSQ 0.01
- Stochastic Oscillator
- CHRS 38.89
- OXSQ 75.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing, and Diversified Insurance.